Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against
Candida albicans
and
Candida glabrata
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 62, Issue 6, Pages -
Publisher
American Society for Microbiology
Online
2018-03-19
DOI
10.1128/aac.02614-17
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
- (2018) Elizabeth A. Lakota et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- CD101 Prophylactic Dose Rationale for Prevention of Aspergillus, Candida, and Pneumocystis Infections
- (2018) Shawn Flanagan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program
- (2017) Michael A. Pfaller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
- (2016) Voon Ong et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization ofIn VitroResistance Development to the Novel Echinocandin CD101 in Candida Species
- (2016) Jeffrey B. Locke et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Echinocandin resistance in Candida spp. isolated from liver transplant recipients
- (2016) Gwénolé Prigent et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
- (2016) Taylor Sandison et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
- (2016) Peter G. Pappas et al. CLINICAL INFECTIOUS DISEASES
- Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, againstCandidaandAspergillusspp., including echinocandin- and azole-resistant isolates
- (2016) Michael A. Pfaller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Oral Presentations
- (2016) MYCOSES
- Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy
- (2015) A. Forastiero et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Positions and Numbers ofFKSMutations in Candida albicans Selectively InfluenceIn VitroandIn VivoSusceptibilities to Echinocandin Treatment
- (2014) M. Lackner et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
- (2014) Jose Vazquez et al. BMC INFECTIOUS DISEASES
- FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
- (2014) N. D. Beyda et al. CLINICAL INFECTIOUS DISEASES
- Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
- (2014) David S. Perlin DRUGS
- Development of echinocandin-resistantCandida albicanscandidemia following brief prophylactic exposure to micafungin therapy
- (2014) M.A. Ruggero et al. Transplant Infectious Disease
- Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure
- (2013) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure
- (2013) James S. Lewis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America
- (2013) Marcio Nucci et al. MYCOSES
- The Presence of anFKSMutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata
- (2012) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
- (2012) M. Ruhnke et al. CLINICAL MICROBIOLOGY AND INFECTION
- Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia
- (2011) David Andes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
- (2011) Annette C Reboli et al. BMC INFECTIOUS DISEASES
- Breakthrough Invasive Candidiasis in Patients on Micafungin
- (2010) C. D. Pfeiffer et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
- (2009) G. Garcia-Effron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis
- (2009) Robert F. Betts et al. CLINICAL INFECTIOUS DISEASES
- Caspofungin-non-susceptible Candida isolates in cancer patients
- (2009) D. P. Kofteridis et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints
- (2008) G. Garcia-Effron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation